MedWatch

Symphogen turns up pipeline before possible IPO

The potential drug Sym004 is still the crown jewel at biotech company Symphogen even though recent trials have narrowed the market. Nevertheless, the rest of the company's pipeline that calls for the largest expenses in the near future.

Foto: Symphogen

Danish biotech company Symphogen is hard at work preparing fundrasing for the fall.

This includes firing up the development of the other products in the company's pipeline, not just the main product Sym004, explains CEO Martin Olin.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier